Style | Citing Format |
---|---|
MLA | Navabi F, et al.. "Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients." Inflammation, vol. 42, no. 1, 2019, pp. 54-63. |
APA | Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M, Mirmosayyeb O, Alsahebfosoul F, Esmaeil N (2019). Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients. Inflammation, 42(1), 54-63. |
Chicago | Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M, Mirmosayyeb O, Alsahebfosoul F, Esmaeil N. "Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients." Inflammation 42, no. 1 (2019): 54-63. |
Harvard | Navabi F et al. (2019) 'Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients', Inflammation, 42(1), pp. 54-63. |
Vancouver | Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M, et al.. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients. Inflammation. 2019;42(1):54-63. |
BibTex | @article{ author = {Navabi F and Shaygannejad V and Abbasirad F and Vaez E and Hosseininasab F and Kazemi M and Mirmosayyeb O and Alsahebfosoul F and Esmaeil N}, title = {Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients}, journal = {Inflammation}, volume = {42}, number = {1}, pages = {54-63}, year = {2019} } |
RIS | TY - JOUR AU - Navabi F AU - Shaygannejad V AU - Abbasirad F AU - Vaez E AU - Hosseininasab F AU - Kazemi M AU - Mirmosayyeb O AU - Alsahebfosoul F AU - Esmaeil N TI - Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients JO - Inflammation VL - 42 IS - 1 SP - 54 EP - 63 PY - 2019 ER - |